Drug
Bay3498264
Bay3498264: highest development phase Phase 1, developed by Bayer. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Bayer
Trials
| Drug | Phase | Indication |
|---|---|---|
| BAY3498264 NCT06659341 | Phase 1 | Advanced Solid Tumors Harboring KRAS G12C Mutation |
Latest
No recent events.
Follow Bay3498264 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.